




PHARMACEUTICAL 2023

Cue Biopharma Inc.
Rank 209 of 446



The relative strengths and weaknesses of Cue Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cue Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Cue Biopharma Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 103%, being 59% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	77,187
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,549
Liabilities, Non-Current	14,052
Other Assets	12,597
Other Compr. Net Income	-96
Other Expenses	-277
Other Liabilities	0
Other Net Income	214
Other Revenues	1,245
Property and Equipment	1,499
Research and Development	38,578
Selling, General and Administrative Expense	16,169

Output Variable	Value in 1000 USD
Assets	91,283
Liabilities	25,601
Expenses	54,470
Revenues	1,245
Stockholders Equity	65,683
Net Income	-53,010
Comprehensive Net Income	-53,058
Economic Capital Ratio	103%